<?xml version="1.0" encoding="UTF-8"?>
<p>The study was designed as a prospective, open-label, nonrandomized clinical trial in a single center for subjects with ALS. The trial (international number: NCT02193893) was approved (approval code: KB-0012/06/10; 25 January 2010) by the Ethics Committee of the Pomeranian Medical University in Szczecin (Poland) and performed in accordance with the Declaration of Helsinki; all patients provided written informed consent. A total of 12 patients, four females and eight males, between 21 and 65 years old (49.7 Â± 13.08), with sporadic ALS according to the El Escorial Revised Criteria [
 <xref rid="B74-ijms-19-01312" ref-type="bibr">74</xref>] and with a survival prognosis of over 12 months on the basis of general and neurological condition were enrolled in the study. A three-month period after the enrollment was dedicated to natural history observation, during which controlled administration of riluzole (the only ALS treatment registered in Poland) was continued. Patients over 65 were excluded from the study, as it has been previously demonstrated that cell growth of expanded in vitro stem cells is strictly related to the donor's age [
 <xref rid="B75-ijms-19-01312" ref-type="bibr">75</xref>]. Patients with familial ALS, with evidence of any concurrent illness, or receiving any medications that might affect bone marrow were excluded.
</p>
